RAD-140 and Trenbolone Interaction: Avoid | Peptide Database

Join others researching Tretinoin — share findings, ask questions, and learn from real experiences Tretinoin is the gold standard topical retinoid for skin aging and acne, FDA-approved since 1971 for acne vulgaris and later for the treatment of photoaging (fine wrinkles, mottled hyperpigmentation, roughness). As the acid form of vitamin A, it is the most extensively studied topical anti-aging compound in dermatology, backed by decades of clinical evidence. Tretinoin accelerates epidermal cell turnover, stimulates collagen synthesis in the dermis, and improves the overall architecture of photodamaged skin. It has become a cornerstone of the biohacking and skincare optimization community due to its proven ability to reduce fine lines, even out skin tone, and improve skin texture with consistent long-term use. Tretinoin binds to retinoic acid receptors (RARs) in the cell nucleus, specifically RAR-alpha, RAR-beta, and RAR-gamma, which form heterodimers with retinoid X receptors (RXRs). These activated receptor complexes bind to retinoic acid response elements (RAREs) in DNA, modulating the transcription of genes involved in cellular differentiation, proliferation, and apoptosis. In the epidermis, tretinoin accelerates keratinocyte turnover from the typical 28-day cycle to approximately 14-16 days, promoting the shedding of damaged surface cells and their replacement with newer, healthier cells. In the dermis, tretinoin stimulates fibroblast activity, increasing the production of procollagen I and III, fibronectin, and elastin. It also inhibits matrix metalloproteinases (MMPs) that degrade collagen, and promotes angiogenesis, improving dermal blood supply. The net result is thicker, more organized epidermis, increased dermal collagen density, and reduced fine wrinkling.

Used off-label at 0.5mg daily for male pattern hair loss. Clinical trials demonstrate superior efficacy compared to finasteride, with greater increases in target area hair count attributed to dual 5-alpha reductase inhibition and more complete DHT suppression. Strong evidence for regrowth at the vertex region, where DHT-sensitive follicles are most concentrated. The greater DHT suppression achieved by dutasteride may provide additional benefit over finasteride in this area. Effective at slowing frontal hairline recession and improving mid-scalp density. Some evidence suggests dutasteride's dual inhibition provides a modest advantage over finasteride for frontal hair loss, though results vary between individuals. Some men who do not respond adequately to finasteride may benefit from switching to dutasteride, as the additional Type I inhibition provides more complete DHT suppression. Not all finasteride non-responders will respond to dutasteride. FDA-approved at 0.5mg daily for the treatment of symptomatic BPH. Reduces prostate volume by approximately 25% and improves urinary symptoms and flow rate over 6-12 months of treatment. Consistently reduces prostate volume more effectively than finasteride due to dual isoform inhibition, with reductions of 25-30% documented in long-term clinical trials.